Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026
Same author

Iterative immunoprecipitation and phage pre-wash dramatically improve epitope-resolved serology by VirScan.

Frontiers in virology (Lausanne, Switzerland)·2026
Same author

Protein Homeostasis Screen Identifies CK2 Inhibition as a Driver of CARD9 Depletion.

ACS chemical biology·2026
Same author

Author Correction: Sequential immunotherapy: towards cures for autoimmunity.

Nature reviews. Drug discovery·2024
Same author

Sequential immunotherapy: towards cures for autoimmunity.

Nature reviews. Drug discovery·2024
Same author

Calcium regulates acid-sensing ion channel 3 activation by competing with protons in the channel pore and at an allosteric binding site.

Open biology·2022

Related Experiment Video

Updated: Jun 12, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Antihypertensive drug development: current challenges and future opportunities.

Peter U Feig1, Sophie Roy, Robert J Cody

  • 1Cardiovascular Clinical Research, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey 07065-0900, USA. Peter_Feig@merck.com

Journal of the American Society of Hypertension : JASH
|June 12, 2010
PubMed
Summary

Developing new high blood pressure medications faces challenges. This review covers drug discovery and development for novel antihypertensive compounds, crucial for an aging population with rising obesity and diabetes rates.

Related Experiment Videos

Last Updated: Jun 12, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Discovery

Background:

  • Rising rates of obesity and diabetes, coupled with an aging population, are increasing the demand for novel antihypertensive compounds.
  • Hypertension remains a significant global health concern, necessitating continuous innovation in therapeutic strategies.

Purpose of the Study:

  • To review the challenges and opportunities in the drug discovery and development pipeline for novel antihypertensive agents.
  • To provide insights into the progression from initial target identification to clinical testing of potential hypertension treatments.

Main Methods:

  • Literature review of the drug discovery and development process for antihypertensive agents.
  • Analysis of key stages including target identification, lead synthesis, preclinical evaluation, and clinical trials.

Main Results:

  • The review outlines the multi-phase process, from identifying hypertension-linked proteins to synthesizing and testing compounds.
  • Significant resource investment increases exponentially as compounds progress through preclinical safety studies and tiered clinical trials.

Conclusions:

  • Successful development of novel antihypertensive drugs requires navigating complex challenges across all stages.
  • Forecasting future issues impacting antihypertensive drug development is essential for continued therapeutic advancement.